Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Inhye Ahn, Zunqiu Wang, Svitlana Tyekucheva, Kiyomi Mashima, Stacey Fernandes, Vanitha Ramakrishnan, Jessica Li, Linlin Xu, Rameen Beroukhim, Ignaty Leshchiner, Jennifer Brown

Blood (2025) 146 (Supplement 1): 2113.

https://doi.org/10.1182/blood-2025-2113

Published: 2025

Journal Articles

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Jennifer Brown, Robert Black, Hang Phan, Katherine Chapis, Samantha Pazienza, Sandra Re, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Lars van der Veen, Michael Lahn, Philippe Armand

Blood (2025) 146 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2025-3913

Published: 2025

Journal Articles

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Fernanda Santos Azevedo, Kiyomi Mashima, Ava Bidgoli, Paulina Predko, Mariia Mikhaleva, Stephen Martindale, Stacey Fernandes, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Jennifer Brown

Blood (2025) 146 (Supplement 1): 3906.

https://doi.org/10.1182/blood-2025-3906

Published: 2025

Journal Articles

Characterization of IGHV subgroups and their prognostic relevance in CLL

Daniel Sungchul Choi, Uday Aditya Sarkar, Yue Ren, Yinglu Zhou, Roberta S. Azevedo, James Yoon, Kiyomi Mashima, Fernanda Santos Azevedo, Gordon Saksena, Stacey Fernandes, Paulina Predko, Matthew S Davids, Svitlana Tyekucheva, Jennifer Brown, Inhye Ahn

Blood (2025) 146 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2025-3899

Published: 2025

Journal Articles

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Katherine Feder, Jessica Freydman, Yue Ren, Shruti Gajjar, Victor You, David Sirignano, Svitlana Tyekucheva, Andrew Brunner, Jean M. Connors, Daniel Deangelo, Amir Fathi, Jacqueline Garcia, Chi-Joan How, Marlise Luskin, Richard Stone, Virginia Volpe, Michelle Lee, Gabriela Hobbs

Blood (2025) 146 (Supplement 1): 7338.

https://doi.org/10.1182/blood-2025-7338

Published: 2025

Journal Articles

Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup

Nathalie Javidi-Sharifi, Sobana Balasubramanian, Hannah Lee, Paulina Predko, Svitlana Tyekucheva, Amber Mitchell, Stacey Fernandes, Roberta Santos Azevedo, Erin Parry, Catherine Wu, Matthew S Davids, Jennifer Brown

Blood (2025) 146 (Supplement 1): 5682.

https://doi.org/10.1182/blood-2025-5682

Published: 2025

Journal Articles

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Jennifer L. Crombie, Christine E. Ryan, Yue Ren, Svitlana Tyekucheva, Celeste Carey, Aaron Zou, Samantha Normilus, Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon E. Arnason, Alvaro J Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2024) 144 (Supplement 1): 4628.

https://doi.org/10.1182/blood-2024-199234

Published: 2024

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Inhye E. Ahn, Yue Ren, David C. Fisher, Austin I. Kim, Nancy E. Kaddis, Jon E. Arnason, John P. Winters, III, Sobana Balasubramanian, Heather A. Walker, Victoria Patterson, Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 1874.

https://doi.org/10.1182/blood-2024-201668

Published: 2024

Journal Articles

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Daniel Sungchul Choi, Yue Ren, Svitlana Tyekucheva, Stacey M. Fernandes, Mariia Mikhaleva, Kiyomi Mashima, Rayan Fardoun, Samantha J. Shupe, Stephen Martindale, Matthew S. Davids, Jennifer R. Brown, Inhye E. Ahn

Blood (2024) 144 (Supplement 1): 587.

https://doi.org/10.1182/blood-2024-208951

Published: 2024

Journal Articles

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Roberta Santos Azevedo, Mariia Mikhaleva, Kiyomi Mashima, Stephen Martindale, Stacey M. Fernandes, Svitlana Tyekucheva, Inhye E. Ahn, Matthew S. Davids, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 583.

https://doi.org/10.1182/blood-2024-206576

Published: 2024

Journal Articles

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2024) 144 (Supplement 1): 1865.

https://doi.org/10.1182/blood-2024-206556

Published: 2024

Journal Articles

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Mariia Mikhaleva, Svitlana Tyekucheva, Kiyomi Mashima, Stacey M Fernandes, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3270.

https://doi.org/10.1182/blood-2023-173738

Published: 2023

Journal Articles

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

Roberta Santos Azevedo, Francesca Morelli, Kiyomi Mashima, Rayan Fardoun, Svitlana Tyekucheva, Stacey M Fernandes, Samantha J. Shupe, Marissa Terra, Anisha Patel, Joseph Yu, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 3266.

https://doi.org/10.1182/blood-2023-180136

Published: 2023

Journal Articles

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Inhye E Ahn, Yinglu Zhou, Svitlana Tyekucheva, Hannah Cormier, Stacey M Fernandes, Josie Montegaard, Marykate Kilcommons, Jennifer L Crombie, Reid W. Merryman, Erin M Parry, Philippe Armand, David C Fisher, Caron A Jacobson, Matthew S Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 1914.

https://doi.org/10.1182/blood-2023-180788

Published: 2023

Journal Articles

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Kiyomi Mashima, Mariia Mikhaleva, Stacey M Fernandes, Samantha J. Shupe, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown

Blood (2023) 142 (Supplement 1): 6507.

https://doi.org/10.1182/blood-2023-187406

Published: 2023

Journal Articles

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Blood (2023) 142 (5): 421–433.

https://doi.org/10.1182/blood.2022016600

Published: 2023

Includes: Supplemental data

Journal Articles

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Blood (2022) 140 (Supplement 1): 837–838.

https://doi.org/10.1182/blood-2022-168003

Published: 2022

Journal Articles

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Anisha V. Patel, Abirami Vijenthira, Aswin Sekar, Christopher J. Gibson, Stephen P. Martindale, Rayan Fardoun, Svitlana Tyekucheva, Stacey M. Fernandes, Binyamin A. Knisbacher, Cynthia K. Hahn, Gad Getz, Catherine J. Wu, Matthew S. Davids, Jennifer R. Brown

Blood (2022) 140 (Supplement 1): 7038–7040.

https://doi.org/10.1182/blood-2022-162707

Published: 2022

Journal Articles

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Christine E. Ryan, Jennifer L. Crombie, Svitlana Tyekucheva, Mikaela M. McDonough, Josie S. Montegaard, Austin I. Kim, Jacob D. Soumerai, Alvaro J. Alencar, Shruti Bhandari, David C. Fisher, Jennifer R. Brown, Matthew S. Davids

Blood (2022) 140 (Supplement 1): 9871–9872.

https://doi.org/10.1182/blood-2022-169986

Published: 2022

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Molecular determinants of outcome in CLL patients treated on zanubrutinib registration trials

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

SF3B1 mutations are associated with shorter time to first treatment in chronic lymphocytic leukemia

Characterization of IGHV subgroups and their prognostic relevance in CLL

Retrospective real-world analysis of ropeginterferon ALFA-2B use in patients with polycythemia vera and essential thrombocythemia: Practice patterns, tolerance, and outcomes

Nodal progression in CLL: Real-world predictors of richter transformation and identification of a distinct high-risk NP-CLL subgroup

A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)

Low Variant Allele Frequency (VAF) TP53 Mutation (mut) Is Not a Poor Prognostic Marker in CLL Patients Treated with Targeted Therapy

Complex Karyotype, but Not Isolated TP53 mutation, Predicts Overall Survival in Chronic Lymphocytic Leukemia Patients in the Era of Targeted Therapy

Primary Endpoint Evaluation of a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Higher Mutational Burden Is an Independent Predictor of Shorter Time to First Treatment in Untreated Chronic Lymphocytic Leukemia Patients

Investigating the Influence of Germline ATM Variants on Susceptibility to Chronic Lymphocytic Leukemia and Other Malignancies

A Phase 2 Study of Acalabrutinib, Umbralisib, and Ublituximab (AU2) in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Characterizing ATM Aberrations in Chronic Lymphocytic Leukemia (CLL): Prognostic Implications and Sensitivity to PARP Inhibition

Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia

Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only